Vizimpro (dacomitinib) / SFJ Pharma, Pfizer  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vizimpro (dacomitinib) / Pfizer
2012-003590-25: Treatment with a Pan-HER inhibitor in locally advanced/metastatic squamous cell carcinoma of the penis. Trattamento con inibitore Pan-HER nelle neoplasie spinocellulari del pene localmente avanzate/metastatiche.

Ongoing
2
37
Europe
Dacomitinib, PF00299804, Tablet
ISTITUTO NAZIONALE PER LA CURA TUMORI, Fondazione IRCCS Istituto Nazionale dei Tumori
locally advanced/metastatic squamous cell carcinoma of the penis Neoplasie spinocellulari del pene in fase localmente avanzata/metastatica, locally advanced/metastatic squamous cell carcinoma of the penis Neoplasie spinocellulari del pene in fase localmente avanzata/metastatica, Diseases [C] - Cancer [C04]
 
 
2011-004671-37: Clinical Trial to evaluate the safety and efficacy of drug PF299804 in patients with brain tumors Ensayo para evaluar la seguridad y eficacia de la molécula PF299804 en pacientes con tumores cerebrales

Ongoing
2
64
Europe
Dacomitinib, PF-00299804,
GRUPO ESPAÑOL DE INVESTIGACION EN NEUROONCOLOGIA, GEINO, Laboratorio Pfizer
Patients with recurrent glioblastoma Pacientes con glioblastoma recurrente
 
 
2021-003755-41: ERIS- a national study on characterization of EGFR-positive lung cancer

Not yet recruiting
2
200
Europe
Tablet, VIZIMPRO, GIOTRIF
Region Skåne, Sjöberg Foundation, Kamprad Foundation, The Swedish cancer society
EGFR-mutated non-small cell lung cancer (NSCLC) not amenable for curative treatment intention and candidates for EGFR-inhibitor in first line., Lung cancer with an EGFR-mutation., Diseases [C] - Cancer [C04]
 
 
NCT04339829: An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Not yet recruiting
2
50
NA
Dacomitinib
Guangdong Association of Clinical Trials
Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
07/22
08/23
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors

Not yet recruiting
2
770
NA
Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rare Tumor
07/22
07/23
NCT04675008: Central Nervous System(CNS) Efficacy of Dacomitinib

Recruiting
2
30
RoW
Dacomitinib, Vizimpro
Samsung Medical Center
Non Small Cell Lung Cancer, Brain Metastases
09/22
03/23
NCT04504071: Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Recruiting
2
30
RoW
Dacomitinib
Shanghai Chest Hospital
Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer
10/22
12/22
NCT04027647: Phase 2 Study of Dacomitinib in NSCLC

Active, not recruiting
2
118
RoW
Dacomitinib, Vizimpro
National Cancer Centre, Singapore, Pfizer
NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV, Recurrent NSCLC, EGFR Positive Non-Small Cell Lung Cancer
03/26
03/26
CAPLAND, NCT04811001 / 2019-002869-35: Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

Recruiting
2
170
Europe
Osimertinib, Tagrisso, Dacomitinib, Vizimpro
Fondazione Ricerca Traslazionale, Pfizer srl
NSCLC
12/23
12/23
ChiCTR2000039310: Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China

Recruiting
2
208
 
Almonertinib, 110mg, qd ;Dacomitinib, 450mg, qd ;Alectinib, 600mg, bid ;Crizotinib, 250mg, bid ;Zelboraf, 960mg, bid ;Niraparib,200-300mg,qd ;Pyrotinib, 400mg, qd ;Imatinib, 400mg, bid ;Palbociclib, 125mg,*21d, q28d ;Sintilimab, 200mg, q21d ;Atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d
National Cancer Center/National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital of Chinese Academy of Medical Sciences, self-raised
Rare Tumors
 
 
NCT04946968: Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Recruiting
2
104
RoW
Oral Dacomitinib
National Cancer Centre, Singapore, Singapore Translational Cancer Consortium, Cancer Science Institute of Singapore, Genome Institute of Singapore
Advanced Solid Tumours, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
07/25
06/28
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
NCT05271916: First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Recruiting
1/2
140
RoW
Dacomitinib+Anlotinib, Dacomitinib
Shanghai Chest Hospital
Non-Small Cell Lung Cancer (NSCLC)
01/25
05/27

Download Options